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Abstract 
Fibrin is an important matrix protein that provides the backbone to the blood clot, 
promoting tissue repair and wound healing. Its precursor fibrinogen is one of the most 
heterogenous proteins, with an estimated 1 million different forms due to alterations in 
glycosylation, oxidation, single nucleotide polymorphisms, splice variation and other 
variations. Furthermore, ligation by transglutamimase factor XIII (cross-linking) adds to the 
complexity of the fibrin network. The structure and function of the fibrin network is in part 
determined by this natural variation in the fibrinogen molecule, with major effects from slice 
variation and cross-linking. This mini-review will discuss the direct effects of fibrinogen 
DEC and fibrinogen J¶VSOLFHYDULDWLRQRQFORWVWUXFWXUHDQGIXQFWLRQDQGDOVRGLVFXVVWKH
additional role of fibrinogen J¶ DV WKURPERPRGXOLQ II. Furthermore, the effects of cross-
linking on clot function will be described. Splice variation and cross-linking are major 
determinants of the structure and function of fibrin and may therefore impact on diseases 
affecting bleeding, thrombosis and tissue repair.  
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Fibrinogen structure 
Fibrinogen is one of the most heterogeneous proteins due to alterations in 
glycosylation, oxidation, splice variation, single nucleotide polymorphisms amongst other 
variations. Henschen estimated that there could be up to 1 million different forms of 
fibrinogen in the blood circulation[1]. While many of the minor alterations and 
polymorphisms are neutral and do not influence the structure and function of fibrinogen or 
its multimeric form fibrin, some of the larger alterations such as splice variation and 
particular single nucleotide polymorphisms such as ADThr312Ala and BEArg448Lys have 
been shown to influence structure and function of the fibrin clot[2].  
Fibrinogen is a dimer of 6 polypeptides (AD2BE2J2) which are arranged in a long flexible 
protein with three regions (D-E-D) that are connected by coiled coil segments (Fig. 6 from 
Litvinov & Weisel review article in this issue[3]). 
 
 
Splice variations of fibrinogen 
 
Fibrinogen DEC 
By far the largest splice variation occurring in fibrinogen involves the D-chain of the 
protein. In around 1% of all fibrinogen, the normal D-polypeptide which is 610 residues 
long is extended by another 236 residues at the C-terminus, leading to an extended DEC 
chain of 846 residues. This large extension is due to splice variation occurring at the exon 
V/intron E boundary of the AD transcript[4]. The additional polypeptide sequence of the 
DEC variant contains 3 glycosylation sites, further adding to the size and molecular weight 
of the protein. The DEC splice variant has also been called fibrinogen-420 as compared 
with the normal fibrinogen-340, due to its increase in molecular mass. Interestingly, the 
DEC sequence is highly conserved among vertebrates with 93.2% homology in rats, 
70.3% in Xenopus and 52.2% in lamprey fish compared with humans [5]. Its structure has 
been elucidated through crystallography[6], but its functional characteristics have been 
poorly described. The DEC region is susceptible to early proteolysis by plasmin[7] and can 
act as a ligand for neutrophils and monocytes via DME2 and DXE2 integrins[8]. Fibrinogen 
DEC has been shown to produce clots with thinner, more branched fibres with increased 
maximum amplitude in thromboelastometry, which is an indication of increased clot 
stiffness[9]. 
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Fibrinogen J¶DQGFORWVWUXFWXUH 
While DEC is the largest fibrinogen splice variant, by far the most studied fibrinogen 
splice variation occurs in the J-chain. This splice-variation, called J¶ DOVR JB or J57.5), 
occurs at the J-chain C-terminus, where the last AGDV sequence of the regular JA chain is 
substituted with VRPEHPAETEYDSLYPEDDL of the J¶ FKDLQ[10]. The J¶ VSOLFH YDULDWLRQ
occurs in around 10-15% of transcripts, and the majority of J¶ LQ FLUFXODWLRQ RFFXUVDVD
JA/J¶ KHWHURGLPHU ZKHUHDV J¶J¶ KRPRGLPHUV DUH OHVV WKDQ  RI WRWDO ILEULQRJHQ 7KH
average JA/J¶FRQFHQWUDWLRQLVEXWOHYHOVFDQGURSWRRULQFUHDVHXSWR[11]. 
The J¶ H[WHQVLRQFRQIHUV LQFUHDVHGQHJDWLYHFKDUJH WR WKH J-chain C-terminus through a 
high proportion of aspartic and glutamic acid residues and two sulphated tyrosines.  
Fibrinogen J¶ KDV EHHQ VKRZQ WR PRGXODWH FORW VWUXFWXUH LQ D GLUHFW PDQQHU
independently of thrombin[12]. Fibers made with fibrinogen J¶DUH WKLQQHU WLJKWO\ LQWHUNQLW
and the network structure is heterogeneous. This effect on clot structure is caused by 
direct interference of the negatively charged J¶ H[WHQVLRQ ZLWK ILEULQ SRO\PHULVDWLRQ DQG
protofibril formation. Gersh et al. VKRZHGLQFUHDVHGHQGVRU³FDSSLQJ´RIJ¶ILEHUV[13]. The 
J¶ILEHUVSDFNVLJQLILFDQWO\OHVVSURWRILEULOVDQGDUHOHVVVWLIIWKDQJA fibers[14]. While J¶FORWV
are mechanically impaired, they are more resistant to proteolysis by plasmin than JA clots 
due to impaired conversion of plasminogen to plasmin by tissue plasminogen activator on 
J¶ FORWV[15]. The significance of these effects for health and disease is less clear since 
increased levels of fibrinogen J¶ KDYHEHHQDVVRFLDWHGZLWK FRURQDU\DUWHU\GLVHDVHDQG
myocardial infarction on one hand, while decreased levels have been associated with 
venous thrombosis on the other[16]. 
 
Fibrinogen J¶DVWKURPERPRGXOLQ,, 
The fibrinogen J¶ FKDLQ FRQWDLQVDKLJKDIILQLW\ binding site for thrombin exosite II[17]. 
The KD of this interaction is around 100 nM, which compares with a KD of 1.5 PM for the 
lower affinity interaction of thrombin exosite I with the fibrinogen E-region, where the 
fibrinopeptides reside that thrombin cleaves during the conversion to fibrin. In view of the 
plasma concentration of fibrinogen J¶ DURXQG  Q0 DQG WKH DPRXQW RI WKURPELQ
generated in tissue factor triggered clotting of blood plasma (up to 200-300 nM at its 
peak[18]), the thrombin-J¶ELQGLQJUHDFKHVVDWXUDWLRQGXULQJWKHSHDNRIEORRGFRDJXODWLRQ
activity. Fibrinogen J¶ ZDV RULJLQDOO\ GHVFULEHG DV DQWLWKURPELQ , DIWHU LWV LQLWLDO
discovery[19]. This antithrombin activity is caused by the high affinity binding of thrombin 
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to the J¶FKDLQLQWKHILEULQFORWZKLFKtherefore acts as a ³VLQN´IRUWKURPELQDQGHIIHFWLYHO\
reduces the amount of thrombin available for other substrates in the supernatant plasma. 
However, recent studies indicate that the effects of J¶ RQ WKURPELQ DFWLYLW\ LV IDU PRUH
complex, with J¶GLUHFWLQJWKURPELQtowards certain target substrates while inhibiting others. 
$WWKLVSRLQWZHZRXOGOLNHWRLQWURGXFHWKHWHUP³WKURPERPRGXOLQ,,´IRUILEULQRJHQJ¶LQ
this mini-review (Fig. 1). In analogy with thrombomodulin, which binds exosite I on 
thrombin and directs thrombin away from exosite I driven reactions (such as the 
conversion of fibrinogen to fibrin) to exosite II driven reactions (particularly the activation of 
protein C), fibrinogen J¶DOVRVKRZVWKURPERPRGXODWLQJDFWLYLW\)LEULQRJHQJ¶FRPSHWLWLYHO\
inhibits the binding of heparin or glycosaminoglycans to thrombin as their binding site 
closely overlap on exosite II[17]. Recent studies by Kremer et al. showed that J¶SURWHFWV
thrombin from degradation by antithrombin and D2-macroglobulin, thereby increasing 
plasma thrombin generation[20]. Other studies show that fibrinogen J¶LQKLELWWKHDFWLYDWLRQ
of a number of substrates that require interaction with thrombin exosite II. Fibrinogen J¶
has been shown to inhibit the activation of factor VIII[21] and factor V[22] by thrombin. 
Moreover, Omarova et al. showed that fibrinogen J¶ LQFUHDVHVWKHVHQVLWLYLW\RISODVPDWR
the inhibition of clotting to activated protein C[23]. So while J¶ RQ RQH KDQG SURWHFWV
thrombin against degradation and increases thrombin generation in plasma, it inhibits 
exosite II driven procoagulant reactions on the other hand. Exosite I driven reactions such 
as the cleavage of fibrinopeptide A by thrombin remain unaffected[24]. Some of these 
functions are not compatible with antithrombin activity, but highlight a modulating activity of 
thrombin activity by J¶FRQVLVWHQWZLWKWKHLQKLELWLRQRIH[RVLWH,,GLUHFWHGUHDFWLRQVKHQFH
the term thrombomodulin II to more accurately describe the interactions between J¶ DQG
thrombin. Further studies are required to study the effect of J¶RQRWKHUWKURPELQ-mediated 
reactions that have hitherto not yet been analysed. 
 
 
Crosslinking of fibrin 
 
Factor XIII, isopeptide bond formation and fibrin cross-linking 
Cross-linking, resulting from the formation of isopeptide bonds, is catalysed by the 
family of transglutaminases. Unlike the other eight members of this family, which are 
located within tissues, factor XIII (FXIII) is a plasma-specific endo-J-glutamine:H-lysine 
transferase[25]. 
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Isopeptide J-glutamyl-H-lysyl bond formation results from the removal of the ammonia from 
a glutamine residue, leading to the formation of an acyl-enzyme intermediate (Fig. 2A), 
and its replacement with an H-amine group from a lysine residue (Fig. 2B). This bond is 
then irreversible and can only be broken down by proteolysis[25]. Factor XIII is capable of 
cross-linking the fibrin D- and J-chains (Fig. 3A), as well as other substrates onto fibrin 
(Fig. 3B), which affect the overall structure and stability of the fibrin mesh[25]. While factor 
XIII is able to cross-link both fibrin D- and J-chains, the kinetics is different between the two 
chains, with the J-chains being cross-linked at a faster rate than the D-chains[26, 27]. 
 
Fibrin D-D chains cross-linking 
Fibrin D-chains are cross-linked to each other by FXIII via glutamine residues 221, 237, 
328 and 366, and lysine residues 208, 219, 224 with an additional 10 lysine residues in the 
DC domain[25]. The effects of fibrin D-chain cross-linking (Fig. 3A) on clot structure have 
been studied in detail using two different fibrinogen mutants. 
The first, fibrinogen D-251, described in 1998, contained a deletion of D-chain amino 
acids 251-610 where most of cross-linking site are located[28]. Collet et al. recently 
showed that in the presence of FXIII, clots made of fibrin D-251 were denser, with the pore 
size decreasing by 1.8-fold, compared to wild-type fibrin[29]. The viscoelastic properties of 
the clots were also analysed using a torsion pendulum, and in the absence of FXIII, clots 
made of the wild-type fibrin were 2.3-fold stiffer than those made of fibrin D-251. In the 
presence of FXIII, the increase in stiffness was 1.6-fold for fibrin D-251 compared to 2.3-
fold for wild-type fibrin, indicating that fibrin D-chain cross-linking play a role in increasing 
fibrin clot stiffness[29]. 
A more recent study also showed that cross-linking of the fibrin D-chains affects clot 
structure in several ways. Using a fibrinogen mutant (J-3X) unable to generate J-J cross-
links[30] and studying clot microrheology using magnetic tweezers, fibrin D-chain cross-
linking was shown to significantly increase  clot stiffness (storage modulus, *¶E\-fold 
and significantly decrease clot deformation (loss modulus, *¶¶ E\ -fold compared to 
uncross-linked clots[31]. This was suggested to be most likely be due to increased fibre 
tautness observed by electron microscopy in clot formed in the presence of FXIII[31].  
Fibrin D-chain cross-linking was also shown to increase fibre appearance time by 1.3-fold 
in confocal microscopy experiments. Using a turbidity set-up, the time to maximum 
absorbency was significantly lengthened for both the wild-type (2.7-fold) and J-3X fibrin 
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(2.2-fold) in the presence of FXIII, indicating that once polymerisation is complete, D-chain 
cross-linking increases fibre thickness over time[31]. 
Fibrinogen J-3X, alongside the previously mentioned fibrinogen D-251, were used by 
Byrnes et al. to study the effects of D- and J-chains cross-linking on red blood cell retention 
within the clot[32]. Inhibition of FXIII cross-linking did not affect the loss of red blood cells 
in clots made of fibrin D-251, whereas clots made of fibrin J-3X and wild-type both showed 
a reduction of clot weight by around 60%. These data indicate that FXIII-dependent 
retention of red blood cells is mediated by the cross-linking of fibrin D-chains[32]. 
 
Fibrin J-J chains cross-linking 
Fibrin J-chains are cross-linked to each other by FXIII via glutamine residues 398 and 
399, and lysine residue 406[25]. Using confocal microscopy, fibrin J-3X described in the 
previous section (Fig. 3A) was shown to significantly increase fibre density within the 
clot[31]. Whilst cross-linking of wild-type fibrin by FXIII induced a 1.3-fold increase in fibre 
density, no changes were observed in the presence of fibrin J-3X, indicating a specific role 
for the J-chain cross-linking in determining clot fibre density. 
Two earlier studies using this mutant showed a contribution of J-chain cross-linking in 
increasing stiffness of the clot. These studies used whole clot rheology by torsion 
pendulum[30] and single fibre measurement by atomic microscopy[33], and showed an 
increase in fibre and clot stiffness of around 40% due to J-chain cross-linking. 
  
Fibrinolysis inhibitors cross-linking to fibrin 
Fibrinolysis inhibitor D2-antiplamin has been shown to be the main protein responsible 
for inhibiting proteolysis of fibrin clots by plasmin, and is cross-linked by FXIII to lysine 
residue 303 of fibrin D-chain via its glutamine residue 2[25] (Fig. 3B). Cross-linking of fibrin 
by FXIII has been shown to increase the clot lysis time, but this was found to be 
exclusively mediated by cross-linking of D2-antiplamin within the clot[34]. It has recently 
been proposed by Rijken et al. that cross-linking of D2-antiplamin to fibrin by FXIII prevents 
it from being expelled from the clot during the process of clot contraction[35]. As such, D2-
antiplamin density within the fibrin fibres increases during the contraction process, 
rendering the whole clot more resistant to fibrinolysis. There are no studies up to date that 
have investigated the effect(s) of the cross-linking of D2-antiplamin to fibrin on the overall 
structure of the clot. 
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Other fibrinolysis inhibitors (Fig. 3B) cross-linked to fibrin are plasminogen-activator 
inhibitor 2 (PAI-2) and thrombin activatable fibrinolysis inhibitor (TAFI). PAI-2 is cross-
linked by FXIII to lysine residues 148, 176, 183, 230, 413 and 457 of fibrin D-chain via its 
glutamine residues 83 and 86[25]. TAFI is cross-linked to fibrin via its glutamine residues 
2, 5 and 292[25] to fibrin D-chain lysine residues 77, 79 and 212[36]. Neither PAI-2 nor 
TAFI are yet to be shown to have an influence on the fibrin clot structure itself. 
 
Other cross-linking to fibrin 
Numerous other substrates are cross-linked to fibrin by FXIII[25], but only a few have be 
shown to affect the clot structure.  
Fibronectin, an extracellular matrix protein involved in cell adhesion and migration, is 
cross-linked to fibrin D-chains by FXIIIa, via its glutamine residues 3, 4 and 16[37], 
although no lysine residue donors have yet been identified in fibrin. Cross-linking of 
fibronectin to fibrin has been shown to have no effect on clot rigidity, however those clots 
were denser, with smaller pores[37]. A more recent study by Ramanathan et al., in a 
purified system in the absence of FXIII, showed that fibronectin increases the initial rate of 
fibrin polymerisation, leading to the formation of denser clots[38], thought to be more 
resistant to fibrinolysis[39]. 
Thrombospondin-1, an extracellular matrix protein involved in cell adhesion and motility, 
is cross-linked to fibrin D-chains by FXIII, via residues that remain to be determined[40]. 
Ligation of thrombospondin-1 within the fibrin clot was found to reduce the lag-time and 
lead to the formation of denser clots containing thinner fibres, in a dose-dependent 
manner[41], rendering them more resistant to fibrinolysis[39]. 
 
 
Summary 
Fibrinogen, the precursor of the clot matrix protein fibrin, is a highly variable protein that 
is subject to modification by splice-variation and ligation by transglutaminase factor XIII. 
These modifications have major implications for fibrin clot structure and function, impacting 
on diseases of thrombosis and bleeding. Examples include fibrinogen DEC and J¶, the 
latter of which has a number of effects on clotting: J¶ inhibits protofibril formation thereby 
altering clot structure, J¶ binds thrombin and it influences thrombin behaviour towards 
substrates, acting as thrombomodulin II. Another example is the cross-linking of fibrin by 
factor XIII, which has major effects on the mechanical properties of fibrin polymer fibres 
and matrix. These protein modifications serve to diversify the function of a single matrix 
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protein such as fibrinogen or fibrin and could play major roles in aspects of health and 
disease involving these functional variations. 
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Figure Legends 
 
Figure 1: Fibrinogen J¶DVWKURPERPRGXOLQ,, Both fibrinogen JA (green) and J¶RUDQJH
bind thrombin exosite I via a low affinity interaction, but fibrinogen J¶FRQWDLQVDQDGGLWLRQDO
high-affinity binding site for thrombin exosite II. Through its interaction with thrombin 
exosite II, fibrinogen J¶ JDLQV D QXPEHU RI IXQFWLRQDO IHDWXUHV LQFOXGLQJ KLJKHU DIILQLW\
thrombin binding, inhibition of factor V (FV) activation, inhibition of factor VIII (FVIII) 
activation and increased sensitivity of plasma for activated protein C (APC), which can be 
grouped as thrombomodulin II activity. In addition, fibrinogen J¶ DOWHUV FORW VWUXFWXUH E\
GLUHFW LQWHUIHUHQFH ZLWK SURWRILEULO IRUPDWLRQ DQG DFWV DV D WKURPELQ ³VSRQJH´ SURWHFWLQJ
thrombin against degradation by D2-macroglobulin and antithrombin. 
 
Figure 2: Isopeptide bond formation catalysed by FXIIIa. The glutamine residue from a 
fibrin molecule is deaminated (A) and replaced by the H-amino group from the lysine 
residue of an adjacent fibrin molecule (B), to form an isopeptide bond. X: fibrin molecule; 
=: isopeptide bond. 
 
Figure 3: Factor XIII cross-linking of fibrin D- and J-chains, and fibrinolysis inhibitors 
to fibrin. A) Fibrin D-D- and J-J chains cross-linking play a role in clot formation, structure 
and stability. B) Fibrinolysis inhibitors cross-linking, such as D2-antiplasmin, PAI-2 and 
TAFI, play a role in protecting the clot from proteolytic degradation by plasmin. 
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